Any feedback?
Literature summary for 3.4.14.5 extracted from
- Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers (2007), J. Clin. Pharmacol., 47, 998-1004.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | vildagliptin is a novel antidiabetic agent that is an orally active, potent, and selective inhibitor of dipeptidyl peptidase IV, the enzyme responsible for degradation of the incretin hormones. No dose adjustment is necessary when vildagliptin and digoxin are coadministered | Homo sapiens |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| vildagliptin | - |
Homo sapiens |  |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
- |
- |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
